Search

Your search keyword '"James, C. David"' showing total 264 results

Search Constraints

Start Over You searched for: Author "James, C. David" Remove constraint Author: "James, C. David" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
264 results on '"James, C. David"'

Search Results

1. Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases

2. Corrigendum: miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma

4. Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production

5. Supplementary Table S2 from SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression

6. Supplementary Figures S1-S3, Table S1 from SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression

7. Data from SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression

8. Data from NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification

9. Supplementary Figures 1-2 from NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification

10. Data from An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway

12. Supplementary Figure 3 from NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification

13. Data from Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation

15. Supplementary Figures S1 - S2 from Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation

16. Supplementary Methods from Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation

17. Supplementary Table S1 from Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation

18. Data from Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM

19. Data from Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model

20. Data from De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients

22. Supplementary Tables 1-2 from NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification

23. Supplementary Figure 4 from NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification

24. Supplementary Figure 1 from De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients

25. Supplementary Figure 1 from MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma

27. Data from MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma

29. Supplementary Figure 2 from De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients

30. Supplementary Figures 1-7 from Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model

31. Supplementary Methods, Figures 1-9 from An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway

32. Supplementary Figure S1 from Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM

33. Supplementary Figure 1 from Targeted Therapy for BRAFV600E Malignant Astrocytoma

35. Supplementary Figure 3 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

36. Supplementary Tables from Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth

38. Supplementary Methods from Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth

40. Supplementary Figure 9 from Targeted Therapy for BRAFV600E Malignant Astrocytoma

41. Supplementary Figure from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models

42. Supplementary Figures from IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma

43. Supplementary Figure 5 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

44. Supplementary Table 1 from Targeted Therapy for BRAFV600E Malignant Astrocytoma

45. Supplementary Figure 1 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

46. Supplementary Materials and Data from Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations

47. Supplementary Methods, Tables 1 - 3 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

48. Supplemental Table 1 from BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas

49. Supplementary Figure 4 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

50. Supplemental Figure 2 from BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas

Catalog

Books, media, physical & digital resources